Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Safety of parathyroid hormone for the treatment of osteoporosis.

Literature DB >> 18430395

Safety of parathyroid hormone for the treatment of osteoporosis.

Abstract

Teriparatide (recombinant human 1-34 parathyroid hormone) has been registered for the treatment of postmenopausal osteoporosis and osteoporosis in men for more than 5 years, whereas 1-84 parathyroid hormone has just recently been registered in Europe for osteoporosis management. Therefore, more data are available regarding the long-term safety of teriparatide. The issues to be considered are the effects of the registered dose of teriparatide (20 microg/day) on the incidence of hypercalcemia, hypercalciuria, and hyperuricemia, and the US Food and Drug Administration's "black-box" warning regarding osteogenic sarcoma in the rat model. This review discusses these issues and provides the author's extensive clinical experience and advice on the use of teriparatide in clinical practice.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18430395 DOI： 10.1007/s11914-008-0003-y

Source DB: PubMed Journal: Curr Osteoporos Rep ISSN： 1544-1873 Impact factor: 5.096

35 in total

1. Osteosarcoma and teriparatide?

Authors: Kristine D Harper; John H Krege; Robert Marcus; Bruce H Mitlak
Journal: J Bone Miner Res Date: 2007-02 Impact factor: 6.741

Review 2. Vitamin D deficiency.

Authors: Michael F Holick
Journal: N Engl J Med Date: 2007-07-19 Impact factor: 91.245

Review 3. Nephrolithiasis.

Authors: D A Bushinsky
Journal: J Am Soc Nephrol Date: 1998-05 Impact factor: 10.121

4. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy.

Authors: Harald Dobnig; Adrien Sipos; Yebin Jiang; Astrid Fahrleitner-Pammer; Louis-Georges Ste-Marie; J Christopher Gallagher; Imre Pavo; Jingyuan Wang; Erik F Eriksen
Journal: J Clin Endocrinol Metab Date: 2005-04-19 Impact factor: 5.958

5. Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) study.

Authors: Paul D Miller; Stuart L Silverman; Deborah T Gold; Kathleen A Taylor; Peiqi Chen; Rachel B Wagman
Journal: Osteoporos Int Date: 2005-06-25 Impact factor: 4.507

6. Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate.

Authors: Paul D Miller; William J Shergy; Jean-Jacques Body; Peiqi Chen; Mark E Rohe; John H Krege
Journal: J Rheumatol Date: 2005-08 Impact factor: 4.666

7. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.

Authors: John L Vahle; Masahiko Sato; Gerald G Long; Jamie K Young; Paul C Francis; Jeffery A Engelhardt; Michael S Westmore; Yanfei Linda; James B Nold
Journal: Toxicol Pathol Date: 2002 May-Jun Impact factor: 1.902

8. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

Authors: E S Orwoll; W H Scheele; S Paul; S Adami; U Syversen; A Diez-Perez; J M Kaufman; A D Clancy; G A Gaich
Journal: J Bone Miner Res Date: 2003-01 Impact factor: 6.741

9. Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects.

Authors: F L Coe; M J Favus; T Crockett; A L Strauss; J H Parks; A Porat; C L Gantt; L M Sherwood
Journal: Am J Med Date: 1982-01 Impact factor: 4.965

10. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report.

Authors: Timothy A Damron; William G Ward; Andrew Stewart
Journal: Clin Orthop Relat Res Date: 2007-06 Impact factor: 4.176

16 in total

Review 1. Parathyroid hormone analogues in the treatment of osteoporosis.

Authors: Marius E Kraenzlin; Christian Meier
Journal: Nat Rev Endocrinol Date: 2011-07-12 Impact factor: 43.330

Review 2. Glucocorticoid-induced osteoporosis and osteonecrosis.

Authors: Robert S Weinstein
Journal: Endocrinol Metab Clin North Am Date: 2012-05-23 Impact factor: 4.741

Review 3. [Overview of animal researches about the effects of systemic drugs on implant osseointegration].

Authors: Ya-Nan Wang; Ting-Ting Jia; Xin Xu; Dong-Jiao Zhang
Journal: Hua Xi Kou Qiang Yi Xue Za Zhi Date: 2020-04-01

4. Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis.

Authors: Luca Pietrogrande
Journal: Int J Womens Health Date: 2010-08-09

5. Higher serum uric acid is associated with higher lumbar spine bone mineral density in male health-screening examinees: a cross-sectional study.

Authors: Jiwon Hwang; Jung Hye Hwang; Seungho Ryu; Joong Kyong Ahn
Journal: J Bone Miner Metab Date: 2018-01-25 Impact factor: 2.626

6. The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report.

Authors: Takanori Yamamoto; Masanori Taketsuna; Xiaoyan Guo; Masayo Sato; Hideaki Sowa
Journal: J Bone Miner Metab Date: 2013-12-25 Impact factor: 2.626